Fosbretabulin Tromethamine

Known as: 1,3-Dihydroxy-2-(Hydroxymethyl)Propan-2-Aminium 2-Methoxy-5-((1z)-2-(3,4,5-Trimethoxyphenyl)Ethenyl)Phenyl Hydrogen Phosphate, 1,3-Propanediol, 2-Amino-2-(Hydroxymethyl)-, Compd. With 2-Methoxy-5-((1z)-2-(3,4,5-Trimethoxyphenyl)Ethenyl)Phenyl Dihydrogen Phosphate (1:1), CA4P 
The tromethamine salt form of prodrug fosbretabulin, a water-soluble phosphate derivative of a stilbenoid phenol derived from the African bush willow… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Vascular-disrupting agents (VDAs) such as combretastatin A4 phosphate (CA4P) selectively disrupt blood vessels in tumors and… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2007
2007
CONTEXT Anaplastic thyroid cancer (ATC) is extremely aggressive, and no effective treatment is available. Combretastatin A4… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
The molecular and cellular pathways that support the maintenance and stability of tumor neovessels are not well defined. The… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2004
Review
2004
Combretastatin A4 phosphate (CA4P) represents the lead compound in a group of novel tubulin depolymerising agents being developed… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel tubulin-binding agent that has been shown… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE Combretastatin A4 phosphate (CA4P) is a novel vascular targeting agent. Dynamic contrast enhanced magnetic resonance… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE Combretastatin A4 (CA4) phosphate (CA4P) inhibits microtubule polymerization and is toxic to proliferating endothelial… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE Clinical evaluation of novel agents that target tumor blood vessels requires pharmacodynamic end points that measure… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Combretastatin A-4 phosphate (CA4P) is a novel antitumor vascular targeting agent, the first agent of this class of compounds to… (More)
  • figure 2
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND Combretastatin A4 Phosphate (CA4P) is a tubulin binding agent which causes rapid tumour vascular shutdown. It has anti… (More)
Is this relevant?